

17 November 2006

To all pharmaceutical suppliers, hospital pharmacists, medical groups and interested parties

## Consultation on provisional agreement with Mayne Pharma relating to various pharmaceuticals

PHARMAC has entered into a provisional agreement with Mayne Pharma relating to the listing of atracurium besylate, ceftazadime, hydroxocobalamin, ondansetron, leuprorelin and testosterone on the Pharmaceutical Schedule. Details of the proposal are as outlined below:

### Testosterone

- Testosterone patches (Androderm) would be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 February 2007 at the following price and subsidy (ex-manufacturer, ex-GST):

Chemical	Presentation	Brand	Pack size	Price/subsidy
Testosterone	Transdermal patch, 2.5 mg/day	Androderm	60	\$80.00

- Androderm would be protected from delisting or subsidy reduction until 1 February 2010.

### Leuprorelin

- Leuprorelin (Eligard) would be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 July 2007 at the following prices and subsidies (ex-manufacturer, ex-GST):

Chemical	Presentation	Brand	Pack size	Price/subsidy
Leuprorelin	Injection, 7.5 mg (one month)	Eligard	1	\$184.90
Leuprorelin	Injection, 22.5 mg (three month)	Eligard	1	\$554.70
Leuprorelin	Injection, 30 mg (four month)	Eligard	1	\$739.60
Leuprorelin	Injection, 45 mg (six month)	Eligard	1	\$1,109.40

- Eligard would be subject to the same Special Authority restrictions that apply to the currently listed brand of leuprorelin (Lucrin).
- Eligard would be protected from delisting or subsidy reduction until 1 July 2009.

### ***Hydroxocobalamin***

- Hydroxocobalamin (Neo-B12) would be listed in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 February 2007 at the following price and subsidy (ex-manufacturer, ex-GST):

<b>Chemical</b>	<b>Presentation</b>	<b>Brand</b>	<b>Pack size</b>	<b>Price/subsidy</b>
Hydroxocobalamin	Injection, 1 mg in 1 mL	Neo-B12	3	\$10.84

- Neo-B12 would be protected from delisting until 1 February 2010.

### ***Ondansetron hydrochloride***

- Mayne's brand of ondansetron hydrochloride would be listed in Part II of Section H from 1 April 2007 at the following prices (ex-manufacturer, ex-GST):

<b>Chemical</b>	<b>Presentation</b>	<b>Brand</b>	<b>Pack size</b>	<b>Price/subsidy</b>
Ondansetron hydrochloride	Injection, 4 mg in 2 mL	Mayne	5	\$18.00
Ondansetron hydrochloride	Injection, 8 mg in 4 mL	Mayne	5	\$29.00

- Mayne's brand of ondansetron hydrochloride would be protected from delisting until 1 April 2009.

### ***Atracurium besylate***

- Mayne's brand of atracurium besylate would be listed in Part II of Section H from 1 June 2007 at the following prices (ex-manufacturer, ex-GST):

<b>Chemical</b>	<b>Presentation</b>	<b>Brand</b>	<b>Pack size</b>	<b>Price/subsidy</b>
Atracurium besylate	Injection, 25 mg in 2.5 mL	Mayne	5	\$12.55
Atracurium besylate	Injection, 50 mg in 2.5 mL	Mayne	5	\$32.55

- Mayne's brand of atracurium besylate would be protected from delisting until 1 June 2009.

### ***Ceftazadime sodium***


- Mayne's brand of ceftazadime sodium would be listed in Part II of Section H at the following prices as soon as is practicable following registration:

<b>Chemical</b>	<b>Presentation</b>	<b>Brand</b>	<b>Pack size</b>	<b>Price/subsidy</b>
Ceftazidime sodium	Injection, 1 g	Mayne	1	\$9.00
Ceftazidime sodium	Injection, 2 g	Mayne	1	\$18.00

- Mayne's brand of ceftazidime sodium would be protected from delisting until 1 April 2009.

It is anticipated that the proposed changes, if accepted by PHARMAC's Board, would take effect from the dates indicated above. If you wish to make comments for the PHARMAC Board to consider when making its decision on whether to accept this proposal, please forward them to PHARMAC by 5:00 pm, 1 December 2006.

Yours sincerely

A handwritten signature in black ink, appearing to read "Sean Dougherty". The signature is stylized with large, overlapping loops and a long horizontal stroke extending to the right.

Sean Dougherty  
Therapeutic Group Manager